NASDAQ:GRCL
Delisted

Gracell Biotechnologies Stock News

etoro logo Buy GRCL
*Your capital is at risk
$10.25
+0 (+0%)
At Close: May 20, 2024
The consensus price target hints at a 120.9% upside potential for Gracell Biotechnologies Inc. Sponsored ADR (GRCL). While empirical research shows that this sought-after metric is hardly effective, a
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmac
Gracell Biotechnologies (GRCL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutica
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedica
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedi
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pat
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedica
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, Chief Executive Officer Wendy Li - Chief Medical Of
Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various diseases.
Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement an
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE